RNA-seq Profiling of Draining and Metastatic Lymph Nodes in HER2-Positive Breast Cancer Identifies POSTN as a Prognostic Marker

HER2-positive breast cancer is aggressive and associated with poorer survival¹. RNA sequencing (RNA-seq) is widely used in translational oncology². We profiled matched tumor-draining (TDLN) and metastatic lymph nodes (TMLN) from six HER2-positive patients by RNA-seq and performed differential expression with DESeq2 using Benjamini–Hochberg control (FDR